NCT06504394: An ongoing trial by Merck Sharp & Dohme LLC
This trial is ongoing. It must report results 3 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06504394 |
|---|---|
| Title | A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 14, 2024 |
| Completion date | Nov. 8, 2028 |
| Required reporting date | Nov. 8, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |